Share This Page
Drug Price Trends for NDC 00006-5007
✉ Email this page to a colleague
Average Pharmacy Cost for 00006-5007
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| DELSTRIGO 100-300-300 MG TAB | 00006-5007-01 | 92.91428 | EACH | 2026-01-06 |
| DELSTRIGO 100-300-300 MG TAB | 00006-5007-01 | 90.65162 | EACH | 2025-12-17 |
| DELSTRIGO 100-300-300 MG TAB | 00006-5007-01 | 90.71467 | EACH | 2025-11-19 |
| DELSTRIGO 100-300-300 MG TAB | 00006-5007-01 | 90.68881 | EACH | 2025-10-22 |
| DELSTRIGO 100-300-300 MG TAB | 00006-5007-01 | 90.68086 | EACH | 2025-09-17 |
| DELSTRIGO 100-300-300 MG TAB | 00006-5007-01 | 90.70671 | EACH | 2025-08-20 |
| DELSTRIGO 100-300-300 MG TAB | 00006-5007-01 | 90.85431 | EACH | 2025-07-23 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00006-5007
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Novantrone (Mitoxantrone Hydrochloride) Market Analysis and Price Projections
Novantrone (mitoxantrone hydrochloride) is an anthracenedione antineoplastic agent used in the treatment of specific cancers and multiple sclerosis. This analysis examines its current market position and projects future price trends based on patent status, competitive landscape, and regulatory factors.
What is the Current Market Status of Novantrone?
Novantrone (mitoxantrone hydrochloride) is primarily indicated for the treatment of secondary progressive multiple sclerosis, relapsing-remitting multiple sclerosis, and advanced prostate cancer. Its therapeutic action stems from its ability to intercalate into DNA, inhibit topoisomerase II, and generate free radicals, thereby disrupting DNA replication and cell division in rapidly proliferating cells.
Key Indications and Approved Uses
- Multiple Sclerosis (MS): Approved for reducing neurological disability and/or the frequency of clinical exacerbations in patients with secondary progressive, progressive-relapsing, or worsening relapsing-remitting MS.
- Prostate Cancer: Indicated for the palliative treatment of advanced, hormone-refractory prostate cancer.
The drug is administered intravenously. The standard dosage varies depending on the indication and patient factors. For MS, a typical dose is 12 mg/m² administered every three months. For prostate cancer, it is administered at 10-12 mg/m² every 21 to 28 days.
Historical Market Performance
Novantrone was first approved by the U.S. Food and Drug Administration (FDA) in 1987. Its market penetration has been influenced by the development of newer therapeutic agents with potentially improved efficacy and safety profiles, particularly in the oncology space. However, it has maintained a niche in specific MS patient populations and as a palliative option in prostate cancer.
Regulatory Landscape
Novantrone is subject to ongoing regulatory oversight by agencies such as the FDA in the United States and the European Medicines Agency (EMA) in Europe. These agencies monitor post-market surveillance, safety updates, and manufacturing standards.
What is the Patent and Exclusivity Status of Novantrone?
Novantrone, as a branded product (Novantrone), has long since passed its initial patent protection periods. The active pharmaceutical ingredient (API), mitoxantrone hydrochloride, is now largely off-patent, allowing for the introduction of generic versions.
Original Patent Expirations
The original composition of matter patents for mitoxantrone hydrochloride have expired. Generic manufacturers have been able to enter the market following these expirations.
Regulatory Exclusivities
While primary patents have expired, other forms of market exclusivity, such as those related to new formulations or specific indications, may have existed. However, the core compound is readily available for generic production.
Impact of Generic Entry
The availability of generic mitoxantrone hydrochloride has significantly impacted the market dynamics, leading to a decrease in the price of the drug compared to its branded predecessor. Generic competition intensifies price pressure and expands market access for cost-conscious healthcare systems and patients.
Who are the Key Market Players?
The market for mitoxantrone hydrochloride includes both branded and generic manufacturers, as well as distributors.
Branded Manufacturer
- Takeda Pharmaceutical Company: Historically the marketer of the branded product Novantrone. While Takeda may still hold distribution rights in certain regions, the primary competitive pressure comes from generic suppliers.
Generic Manufacturers
The generic market is more fragmented and subject to ongoing competition. Key generic players include companies that specialize in the production of injectable oncology drugs and generics. Specific company names can fluctuate based on manufacturing capabilities, market entry, and supply chain dynamics. Examples of companies historically involved in generic injectable manufacturing that may produce mitoxantrone include:
- Teva Pharmaceutical Industries
- Mylan N.V. (now part of Viatris)
- Fresenius Kabi
- Hikma Pharmaceuticals
It is crucial for market participants to monitor the FDA's Abbreviated New Drug Application (ANDA) approvals and market filings to identify active generic manufacturers at any given time.
Distributors
Pharmaceutical wholesalers and specialty distributors play a critical role in the supply chain, ensuring that mitoxantrone hydrochloride reaches pharmacies, hospitals, and clinics.
What are the Competitive Threats and Alternatives?
The competitive landscape for mitoxantrone hydrochloride is defined by both direct generic competition and the availability of alternative therapies for its approved indications.
Direct Competition (Generic Mitoxantrone)
The most significant competitive threat is the presence of multiple generic manufacturers producing mitoxantrone hydrochloride. This leads to commoditization of the product and intense price competition. The availability of multiple generic suppliers ensures a consistent downward pressure on pricing.
Alternative Therapies for Multiple Sclerosis
For secondary progressive and relapsing forms of MS, several disease-modifying therapies (DMTs) have emerged, offering different mechanisms of action and varying efficacy/safety profiles. These include:
- Injectable Therapies: Interferon-beta (e.g., Avonex, Rebif, Betaseron), Glatiramer Acetate (Copaxone).
- Oral Therapies: Fingolimod (Gilenya), Teriflunomide (Aubagio), Dimethyl Fumarate (Tecfidera), Siponimod (Mayzent), Ozanimod (Zeposia).
- Infusion Therapies: Natalizumab (Tysabri), Ocrelizumab (Ocrevus), Rituximab (Rituxan – off-label in some regions for MS but approved for other indications).
The introduction and widespread adoption of these newer DMTs, particularly those with higher efficacy or more convenient administration, have reduced the market share for older agents like mitoxantrone in broader MS treatment. Mitoxantrone remains a consideration for specific patient profiles or when other options are contraindicated or ineffective.
Alternative Therapies for Advanced Prostate Cancer
In the oncology sector, mitoxantrone is used in a palliative setting for hormone-refractory prostate cancer. The competitive landscape here is dynamic and includes:
- Chemotherapy Agents: Docetaxel (Taxotere), Cabazitaxel (Jevtana).
- Hormonal Therapies: Newer generation androgen receptor inhibitors like Abiraterone Acetate (Zytiga), Enzalutamide (Xtandi), Apalutamide (Erleada), and Darolutamide (Nubeqa).
- Radiopharmaceuticals: Radium-223 dichloride (Xofigo) for bone metastases.
The development of more targeted therapies and agents with improved survival benefits has shifted treatment paradigms for advanced prostate cancer, potentially limiting the use of older cytotoxic agents like mitoxantrone.
What are the Price Drivers and Projections for Novantrone?
The pricing of mitoxantrone hydrochloride is primarily driven by generic competition, manufacturing costs, and demand from its specific therapeutic niches.
Current Pricing Landscape
As a largely genericized injectable, Novantrone's price is significantly lower than during its branded exclusivity period. Pricing is highly competitive among generic manufacturers. Wholesale acquisition cost (WAC) for generic mitoxantrone hydrochloride typically ranges from $50 to $150 per vial (e.g., 20 mg/10 mL vial), depending on the manufacturer, purity, and volume purchased. This is a substantial reduction from the branded product's historical pricing.
Factors Influencing Future Pricing
- Manufacturing Costs: The cost of raw materials, complex sterile manufacturing processes for injectables, and regulatory compliance are baseline cost drivers.
- Competition Intensity: The number of active generic manufacturers will continue to dictate price levels. A high number of suppliers generally leads to lower prices.
- Demand: While overall demand for mitoxantrone may be constrained by newer alternatives, a stable or modest demand in its specific niches will support continued production and pricing.
- Supply Chain Stability: Disruptions in the supply chain, due to raw material shortages or manufacturing issues with key players, can temporarily impact availability and potentially price. However, given the generic nature, other manufacturers can often fill gaps.
- Regulatory Changes: Any significant changes in manufacturing standards or post-market surveillance requirements could impact production costs.
- Reimbursement Policies: Payer policies for injectable drugs can influence market access and indirectly affect pricing strategies, although direct price controls are more common in some international markets than in the U.S.
Price Projections
Given the mature, genericized nature of the mitoxantrone hydrochloride market, significant price increases are unlikely. Instead, prices are expected to remain relatively stable with potential for minor fluctuations due to supply and demand dynamics.
- Short-Term (1-3 years): Expect prices to remain within the current range of $50-$150 per vial. Minor price adjustments may occur based on specific manufacturer strategies or supply-side events.
- Medium-Term (3-5 years): Continued generic competition will likely prevent substantial price increases. The market may see some consolidation among manufacturers, but overall pricing pressure will persist. Prices are projected to stay within or slightly above the current range, potentially reaching $60-$170 per vial.
- Long-Term (5+ years): The long-term outlook is dependent on the sustained clinical utility of mitoxantrone in its niche indications. If newer, more effective, or safer treatments largely supplant its use, demand could decline, potentially leading to fewer manufacturers and a less predictable pricing environment, or conversely, remaining stable if it fills a clear unmet need for specific patient subsets. However, assuming continued utility, prices will likely remain relatively stable, mirroring inflation.
The primary driver for price stabilization will be the continued presence of multiple generic suppliers, ensuring a competitive marketplace.
Key Takeaways
- Novantrone (mitoxantrone hydrochloride) is an established, off-patent injectable drug used for specific indications in multiple sclerosis and prostate cancer.
- The market is dominated by generic competition, significantly reducing pricing from its branded past.
- Key competitors include numerous generic manufacturers, with Takeda being the historical branded marketer.
- Competitive threats include a wide array of newer, often more advanced, therapies for both MS and prostate cancer.
- Pricing is expected to remain stable, ranging from $50-$170 per vial over the next five years, driven by ongoing generic competition and manufacturing costs, with significant price increases unlikely.
Frequently Asked Questions
-
What is the current average wholesale acquisition cost (WAC) for a single vial of generic mitoxantrone hydrochloride? The average WAC for a single vial of generic mitoxantrone hydrochloride (e.g., 20 mg/10 mL) typically falls between $50 and $150, though this can vary by manufacturer and distributor.
-
Are there any remaining market exclusivities for Novantrone that could impact generic entry? The primary composition of matter patents for mitoxantrone hydrochloride have expired, allowing for broad generic entry. While specific formulation or indication patents might have existed, they do not prevent generic competition on the core API.
-
How has the development of new disease-modifying therapies for Multiple Sclerosis affected the demand for mitoxantrone? The introduction of numerous newer and often more targeted or effective DMTs has reduced the overall market share for older agents like mitoxantrone in the broader MS patient population. It remains relevant for specific patient profiles and treatment lines.
-
What are the primary cost drivers for generic mitoxantrone hydrochloride manufacturers? Primary cost drivers include the procurement of raw materials, stringent sterile injectable manufacturing processes, quality control, regulatory compliance, and distribution logistics.
-
Can we expect significant price increases for mitoxantrone hydrochloride in the next five years? Significant price increases are not anticipated. The market is expected to remain competitive with stable pricing within the $60-$170 per vial range over the next five years, driven by the sustained presence of generic manufacturers.
Citations
[1] U.S. Food & Drug Administration. (n.d.). Drug Approvals and Databases. Retrieved from www.fda.gov (Accessed various dates for database searches) [2] National Institutes of Health. (n.d.). DailyMed - Drug Label Information. Retrieved from dailymed.nlm.nih.gov (Accessed various dates for specific drug labels and indications) [3] Pharmaceutical market research reports and pricing databases (e.g., IQVIA, Definitive Healthcare, GoodRx Pro). (Proprietary data, accessed as part of professional analysis). [4] Takeda Pharmaceutical Company. (Various dates). Company Investor Relations and Product Information. Retrieved from www.takeda.com (Historical product information). [5] Generic drug manufacturer websites and regulatory filings (e.g., Teva Pharmaceuticals, Viatris, Fresenius Kabi). (Accessed various dates for product availability and indications).
More… ↓
